UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 10-Q

(Mark One)

☒	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended

~~September~~December 3031, 2020

☐	TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

	For the transition period from ________________ to _____________________

Commission File Number

333-188152

BIONOVATE TECHNOLOGIES CORP.

(Exact name of registrant as specified in its charter)

Nevada		33-1229553
(State or other jurisdiction of incorporation or organization)		(IRS Employer Identification No.)

Gewerbestrasse 10, Cham, Switzerland		6330
(Address of principal executive offices)		(Zip Code)

(646)224-1160

(Registrant’s telephone number, including area code)

N/A

(Former name, former address and former fiscal year, if changed since last report)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
None	None	None

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. ☒ YES ☐ NO

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). ☒ YES ☐ NO

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer	☐	Accelerated filer	☐
Non-accelerated filer	☒	Smaller reporting company	☒
		Emerging growth company	☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act) ☐ YES ☒ NO

Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date.

5945,~~423~~603,598 common shares issued and outstanding as of ~~October~~January 2622, ~~2020~~2021.

TABLE OF CONTENTS

PART I - FINANCIAL INFORMATION		3
Item 1.	Financial Statements	3
Item 2.	Management's Discussion and Analysis of Financial Condition or Plan of Operation	1213
Item 3.	Quantitative and Qualitative Disclosures About Market Risk	1718
Item 4.	Controls and Procedures	1718
PART II - OTHER INFORMATION		1819
Item 1.	Legal Proceedings	1819
Item 1A.	Risk Factors	1819
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	1819
Item 3.	Defaults Upon Senior Securities	1819
Item 4.	Mine Safety Disclosures	1819
Item 5.	Other Information	1819
Item 6.	Exhibits	1920
SIGNATURES		2021

2 ~~Table of Contents~~

PART I - FINANCIAL INFORMATION

Item 1. Financial Statements

Bionovate Technologies Corp

BALANCE SHEETS

(Unaudited)

	September 30,			June 30,
	December 31,			June 30,
	2020			2020
ASSETS
Current Assets
Cash	$	-		$	-
Total Current Assets		-			-
TOTAL ASSETS	$	-		$	-
LIABILITIES AND STOCKHOLDERS' DEFICIT
Current Liabilities
Accounts payable and accrued liabilities	$	~~230~~251,~~324~~130		$	211,290
Due to related party		315,~~840~~468			-
Convertible notes payable		185,375			185,375
Total Current Liabilities		~~419~~451,~~539~~973			396,665
TOTAL LIABILITIES		~~419~~451,~~539~~973			396,665
Stockholders' Deficit
Preferred stock: 90,000,000 authorized; $0.0001 par value - no shares issued and outstanding		-			-
Common stock: 100,000,000 authorized; $0.0001 par value
59,423,598 and 59,423,598 shares issued and outstanding		5,942			5,942
45,603,598 and 59,423,598 shares issued and outstanding		4,560			5,942
Additional paid in capital		2,~~295~~297,~~633~~015			2,295,633
Accumulated deficit		(2,~~721~~753,~~114~~548	)		(2,698,240	)
Total Deficit		(~~419~~451,~~539~~973	)		(396,665	)
TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT	$	-		$	-

The accompanying notes are an integral part of these unaudited financial statements

Table of Contents

Bionovate Technologies Corp

STATEMENT OF OPERATIONS

(Unaudited)

	Three Months Ended						Six Months Ended
	September 30,
	December 31,						December 31,
	2020			2019			2020			2019
Revenues	$	-		$	-		$	-		$	-
Operating Expenses
Professional		3,622			13,412
General and administration		850			-			850			-
Total operating expenses		3,622			13,412
Professional		19,838			10,950			23,460			24,362
Net loss from operations		(3,622	)		(13,412	)
Total operating expenses		20,688			10,950			24,310			24,362
Other income (expense)
Net loss from operations		(20,688	)		(10,950	)		(24,310	)		(24,362	)
Realized foreign currency gain		-			68
Other income (expense)
Interest expense		(19,252	)		(16,032	)
Realized foreign currency gain (loss)		(282	)		(175	)		(282	)		(107	)
Total other expense		(19,252	)		(15,964	)
Interest expense		(11,464	)		(34,444	)		(30,716	)		(50,476	)
Net loss before taxes		(22,874	)		(29,376	)
Total other expense		(11,746	)		(34,619	)		(30,998	)		(50,583	)
Net loss	$	(22,874	)	$	(29,376	)
Net loss before taxes		(32,434	)		(45,569	)		(55,308	)		(74,945	)
Basic and dilutive loss per share
Net loss	$	(32,434	)	$	(45,569	)	$	(55,308	)	$	(74,945	)
Net loss	$	(0.00	)	$	(0.00	)
Basic and dilutive loss per share
Weighted average number of shares outstanding		59,423,598			15,579,749
Net loss	$	(0.00	)	$	(0.29	)	$	(0.00	)	$	(0.48	)
Weighted average number of shares outstanding		56,869,902			155,798			58,146,750			155,798

The accompanying notes are an integral part of these unaudited financial statements

Table of Contents

Bionovate Technologies Corp

STATEMENT OF STOCKHOLDERS’ DEFICIENCY

(Unaudited)

For the Three and Six Months Ended ~~September~~December 3031, 2020

							Additional
	Common Stock						Paid in		Accumulated
	Shares			Amount			Capital		Deficit			Total
Balance, June 30, 2020		59,423,598		$	5,942		$	2,295,633	$	(2,698,240	)	$	(396,665	)
Net loss		-			-			-		(22,874	)		(22,874	)
Balance, September 30, 2020		59,423,598		$	5,942		$	2,295,633	$	(2,721,114	)	$	(419,539	)
Cancellation of shares		(13,820,000	)		(1,382	)		1,382		-			-
Net loss		-			-			-		(32,434	)		(32,434	)
Balance, December 31, 2020		45,603,598		$	4,560		$	2,297,015	$	(2,753,548	)	$	(451,973	)

For the Three Months Ended September 30, 2019

					Additional
	Common Stock				Paid in		Accumulated
	Shares		Amount		Capital		Deficit			Total
Balance, June 30, 2019		155,798	$	15	$	2,243,891	$	(2,576,195	)	$	(332,289	)
Beneficial conversion feature		-		-		526		-			526
Net loss		-		-		-		(29,376	)		(29,376	)
Balance, September 30, 2019		155,798	$	15	$	2,244,417	$	(2,605,571	)	$	(361,139	)

The accompanying notes are an integral part of these unaudited financial statements

Table of Contents

For the Three and Six Months Ended December 31, 2019

					Additional
	Common Stock				Paid in		Accumulated
	Shares		Amount		Capital		Deficit			Total

Balance, June 30, 2019		155,798	$	15	$	2,243,891	$	(2,576,195	)	$	(332,289	)

Beneficial conversion feature		-		-		526		-			526
Net loss		-		-		-		(29,376	)		(29,376	)

Balance, September 30, 2019		155,798	$	15	$	2,244,417	$	(2,605,571	)	$	(361,139	)

Beneficial conversion feature		-		-		18,892		-			18,892
Net loss		-		-		-		(45,569	)		(45,569	)

Balance, December 31, 2019		155,798	$	15	$	2,263,309	$	(2,651,140	)	$	(387,816	)

The accompanying notes are an integral part of these unaudited financial statements

Table of Contents

Bionovate Technologies Corp

STATEMENT OF CASH FLOWS

(Unaudited)

	Three Months Ended
	Six Months Ended
	September 30,
	December 31,
	2020			2019
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$	(2255,~~874~~308	)	$	(2974,~~376~~945	)
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:
Expenses paid by convertible notes		-			~~526~~19,418
Expenses paid by related party		315,~~840~~468			-
Amortization of debt discount		-			~~526~~19,418
Foreign currency adjustment		-282			~~(68~~107	)
Changes in operating assets and liabilities:
Accounts payable and accrued liabilities		1939,~~034~~558			2836,~~392~~002
Net cash provided by operating activities		-			-
Net change in cash and cash equivalents		-			-
Cash and cash equivalents, beginning of period		-			-
Cash and cash equivalents, end of period	$	-		$	-
Supplemental cash flow information
Cash paid for interest	$	-		$	-
Cash paid for taxes	$	-		$	-
Non-cash transactions:
Beneficial conversion feature	$	-		$	~~526~~19,418
Cancellation of shares	$	1,382		$	-

The accompanying notes are an integral part of these unaudited financial statements

67 Table of Contents

Bionovate Technologies Corp

NOTES TO THE FINANCIAL STATEMENTS

~~September~~December 3031, 2020

NOTE 1 – NATURE AND CONTINUANCE OF OPERATIONS

Bionovate Technologies Corp. (the “Company”, or the “Corporation”) was incorporated in the state of Nevada, United States on October 24, 2012 under the name MJP International Ltd. On December 1, 2017, the Company’s corporate name was changed to Bionovate Technologies Corp.

The Corporation was formed and organized to capitalize on new opportunities found in the North American market for light-emitting diode (“LED”) lighting. With China as the manufacturing backbone of future LED products, the Corporation has set up an office in Guangzhou, China in search of high-quality products offered by reputable manufacturers to be introduced to Canada, the United States, and abroad. The Corporation has set out further details of the acquisition below as well as in Notes 3 and 4 to these consolidated financial statements.

Bionovate Technologies Corp. focuses on investments and the marketing of patents and licenses which bring healthcare and lifestyle diagnostics to your smartphone. With strong emphasis on digital transformation, the company intends to build an FDA-approved ecosystem of medical devices, biosensors and mobile applications to turn tests that were previously only done in physical labs into tests that can be carried through by anyone with a mobile device.

On October 7, 2020, Bionovate Technologies Corp. (the “Company”) entered into a Share Exchange Agreement (the “Share Exchange Agreement”) facilitated between Evergreen Solutions, Ltd, a private Company (“Evergreen”), and Human Data AG, a private Switzerland Company (“Human Data”).

Pursuant to the Share Exchange Agreement, in exchange for the acquisition of all of the outstanding Company shares which Evergreen owns, to wit, 54,270,000 shares (the “Exchange Shares”), the Company will receive 12,500 shares of Digital Diagnostics AG (“Digital”) owned by Human Data, which equates to 25% of the currently issued shares of Digital.

The Share Exchange Agreement contains customary representations and warranties made by the Company, on the one hand, and Evergreen and Human Data on the other hand, made solely for the benefit of the other, which in certain cases are subject to specified exceptions and qualifications contained in the Share Exchange Agreement or in information provided pursuant to certain disclosure schedules to the Share Exchange Agreement

The share exchange agreement gave the other party 90 days to transfer shares of Digital to Bionovate. Bionovate did not receive these shares yet and does not own any of Digital Diagnostics as of the date of this report.

GOING CONCERN

The accompanying financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America, which contemplate continuation of the Company as a going concern. However, the Company has an accumulated deficit at ~~September~~December 3031, 2020 of $2,~~721~~753,~~114~~548, is in a net liability position and needs cash to maintain its operations.

These factors raise substantial doubt about the Company’s ability to continue as a going concern. The accompanying financial statements do not include any adjustments that might result from the outcome of this uncertainty. The Company’s continued existence is dependent upon management’s ability to develop profitable operations, continued contributions from the Company’s executive officers to finance its operations and the ability to obtain additional funding sources to explore potential strategic relationships and to provide capital and other resources for the further development and marketing of the Company’s products and business.

NOTE 2– SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation

The accompanying unaudited financial statements have been prepared in accordance with generally accepted accounting principles for interim financial information and with the instructions for Form 10-Q and Article 210 8-03 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. In the opinion of management, all adjustments considered necessary for a fair presentation have been included. All such adjustments are of a normal recurring nature. Operating results for the three months ended ~~September~~December 3031, 2020, are not necessarily indicative of the results that may be expected for the fiscal year ending June 30, 2021. For further information, refer to the financial statements and footnotes thereto included in the Corporation’s filed Form 10-K for the year ended June 30, 2020.

78 Table of Contents

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect application of policies and the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the year. Actual results could differ from these estimates. Estimates and their underlying assumptions are reviewed on an ongoing basis. Changes in estimates are recorded in the accounting period in which they are determined. The critical accounting estimates and assumptions in the accompanying unaudited condensed interim financial statements include the provision for unpaid loss and loss adjustment expenses which may result from product warranty provisions; valuation of deferred income taxes; valuation and impairment assessment of intangible assets; goodwill recoverability; and deferred acquisition costs.

Fair Value of Financial Instrument

The Corporation follows FASB ASC 820, Fair Value Measurements and Disclosures, for all financial instruments and non-financial instruments accounted for at fair value on a recurring basis. This new accounting standard establishes a single definition of fair value and a framework for measuring fair value, sets out a fair value hierarchy to be used to classify the source of information used in fair value measurement and expands disclosures about fair value measurements required under other accounting pronouncements. It does not change existing guidance as to whether or not an instrument is carried at fair value. The Corporation defines fair value as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date.

When determining the fair value measurements for assets and liabilities, which are required to be recorded at fair value, the Corporation considers the principal or most advantageous market in which the Corporation would transact and the market-based risk measurements or assumptions that market participants would use in pricing the asset or liability, such as inherent risk, transfer restrictions and credit risk.

The Corporation applies FASB ASC 825, Financial Instruments, which allows companies to choose to measure eligible financial instruments and certain other items at fair value that are not required to be measured at fair value. The Corporation has not elected the fair value option for any eligible financial instruments.

Basic and Diluted Loss per Common Stock

FASB ASC 260 requires dual presentation of basic and diluted earnings per share (EPS) with a reconciliation of the numerator and denominator of the EPS computations. Basic earnings per share amounts are based on the weighted average shares of common stock outstanding. If applicable, diluted earnings per stock would assume the conversion, exercise or issuance of all potential common stock instruments such as options, warrants and convertible securities, unless the effect is to reduce a loss or increase earnings per share. Diluted net income (loss) per common stock on the potential exercise of the equity-based financial instruments is not presented where anti-dilutive.

For the ~~three~~six months ended ~~September~~December 3031, 2020 and 2019, the following common stock equivalents were excluded from the computation of diluted net loss per share as the result of the computation was anti-dilutive.

	September 30,		September 30,
	December 31,		December 31,
	2020		2019
	(shares)		(shares)
Convertible notes		26,740,500		2427,~~575~~544,~~800~~200

8 Table of Contents

NOTE 3 – ACCOUNTS PAYABLE AND ACCRUED LIABILITEIS

ASAs of ~~September~~December 3031, 2020, and June 30, 2020, accounts payable and accrued liabilities consisted of as follows,

	September 30,		June 30,
	December 31,		June 30,
	2020		2020
Accounts payable	$	3847,~~138~~479	$	25,702
Accrued expenses		-		12,654
Accrued expense		-		12,654
Accrued interest		~~151~~162,~~161~~626		131,909
Due to a former related party		41,025		41,025
	$	~~230~~251,~~324~~130	$	211,290

NOTE 4 – CONVERTIBLE NOTE

Convertible notes payable at September 30, 2020 and June 30,2020, consists of the following:

	September 30,		June 30,
	2020		2020
Dated November 1, 2016	$	4,439	$	4,439
Dated January 1, 2017 - 1		-		-
Dated January 1, 2017 - 2		-		-
Dated June 30, 2017		9,969		9,969
Dated April 1, 2018 - 1		10,000		10,000
Dated April 1, 2018 - 2		10,000		10,000
Dated June 30, 2018		28,376		28,376
Dated July 5, 2018 - 1		30,000		30,000
Dated July 5, 2018 - 2		15,000		15,000
Dated July 5, 2018 - 3		15,000		15,000
Dated December 31, 2018		17,302		17,302
Dated March 31, 2019		1,000		1,000
Dated June 30, 2019		17,037		17,037
Dated September 30, 2019		526		526
Dated December 31, 2019		18,892		18,892
Dated March 31, 2020		5,834		5,834
Dated June 30, 2020		2,000		2,000
Total convertible notes payable		185,375		185,375
Less: Unamortized debt discount		-		-
Total convertible notes		185,375		185,375
Less: current portion of convertible notes		185,375		185,375
Long-term convertible notes	$	-	$	-

For the three months ended September 30, 2020 and 2019, the Company recognized interest expense of $19,252 and $15,506 and amortization of discount, included in interest expense, of $0 and $526, respectively. As of September 30, 2020, and June 30, 2020, the Company recorded accrued interest of $151,161 and $131,909, respectively

Table of Contents

NOTE 4 – CONVERTIBLE NOTE

Convertible notes payable at December 31, 2020 and June 30,2020, consists of the following:

	December 31,		June 30,
	2020		2020
Dated November 1, 2016	$	4,439	$	4,439
Dated June 30, 2017		9,969		9,969
Dated April 1, 2018 - 1		10,000		10,000
Dated April 1, 2018 - 2		10,000		10,000
Dated June 30, 2018		28,376		28,376
Dated July 5, 2018 - 1		30,000		30,000
Dated July 5, 2018 - 2		15,000		15,000
Dated July 5, 2018 - 3		15,000		15,000
Dated December 31, 2018		17,302		17,302
Dated March 31, 2019		1,000		1,000
Dated June 30, 2019		17,037		17,037
Dated September 30, 2019		526		526
Dated December 31, 2019		18,892		18,892
Dated March 31, 2020		5,834		5,834
Dated June 30, 2020		2,000		2,000
Total convertible notes payable		185,375		185,375

Less: Unamortized debt discount		-		-
Total convertible notes		185,375		185,375

Less: current portion of convertible notes		185,375		185,375
Long-term convertible notes	$	-	$	-

For the six months ended December 31, 2020 and 2019, the Company recognized interest expense of $30,716 and $31,058 and amortization of discount, included in interest expense, of $0 and $19,418, respectively. As of December 31, 2020, and June 30, 2020, the Company recorded accrued interest of $162,626 and $131,909, respectively.

Dated November 1, 2016

On November 1, 2016, the Company issued a convertible note with a conversion price of $0.005 to extinguish debt of $18,239. The convertible note is unsecured, bears interest at 4% per annum and due and payable on November 1, 2017. The Company recorded a discount on the convertible note due to a beneficial conversion feature of $18,239.

Dated June 30, 2017

On June 30, 2017, the Company issued a convertible note with a conversion price of $0.01 to pay operating expenses of $9,969. The convertible note is unsecured, bears interest at 35% per annum, has no maturity date and due on demand. The Company recorded a discount on the convertible note due to a beneficial conversion feature of $9,969.

Table of Contents

Dated April 1, 2018 – 1 and 2

On April 1, 2018, the Company issued 2 convertible notes totaling of $20,000 with a conversion price of $$0.01 to pay a purchase of a patent of $10,000. The convertible note is unsecured, bears interest at 45% per annum, has no maturity date and is due on demand. The Company recorded a discount on the convertible note due to a beneficial conversion feature of $20,000.

Dated June 30, 2018

On June 30, 2018, the Company issued a convertible note with a conversion price of $0.01 to pay operating expenses of $28,376. The convertible note is unsecured, bears interest at 30% per annum, has no maturity date and is due on demand. The Company recorded a discount on the convertible note due to a beneficial conversion feature of $28,376.

Dated July 5, 2018 – 1, 2 and 3

On June 30, 2018, the Company issued 3 convertible notes totaling of $60,000 with a conversion price of $0.01 to extinguish amounts due to related parties of $145,523. The convertible notes are unsecured, bears interest at 30% per annum, has no maturity date and is due on demand. The Company recorded a discount on the convertible notes due to a beneficial conversion feature of $60,000.

Dated December 31, 2018

On December 31, 2018, the Company issued a convertible note with a conversion price of $0.005 to pay operating expenses of $17,302. The convertible note is unsecured, bears interest at 35% per annum, has no maturity date and is due on demand. The Company recorded a discount on the convertible notes due to a beneficial conversion feature of $17,302.

Dated March 31, 2019

On March 31, 2019, the Company issued a convertible note with a conversion price of $0.01 to pay operating expenses of $6,427. The convertible note is unsecured, bears interest at 20% per annum, has no maturity date and is due on demand. The Company recorded a discount on the convertible notes due to a beneficial conversion feature of $6,427.

Effective January 28, 2020, the Company amended a convertible note. The Note reduces the interest rate from 20% to 0 and changes the conversion price from $0.01 to $0.0001.

Effective January 28, 2020, the Note of $6,427 was assigned to Evergreen Solutions Ltd., and $5,427 was immediately converted for the issuance of 54,270,000 shares of common stock of the Company resulting in a change of control.

Dated June 30, 2019

On June 30, 2019, the Company issued a convertible note with a conversion price of $0.005 to pay operating expenses of $17,037. The convertible note is unsecured, bears interest at 35% per annum, has no maturity date and is due on demand. The Company recorded a discount on the convertible notes due to a beneficial conversion feature of $17,037.

10 Table of Contents

Dated September 30, 2019

On September 30, 2019, the Company issued a convertible note with a conversion price of $0.005 to pay operating expenses of $526. The convertible note is unsecured, bears interest at 35% per annum, has no maturity date and is due on demand. The Company recorded a discount on the convertible notes due to a beneficial conversion feature of $526.

Dated December 31, 2019

On December 31, 2019, the Company issued a convertible note with a conversion price of $0.005 to pay operating expenses of $18,892. The convertible note is unsecured, bears interest at 35% per annum, has no maturity date and is due on demand. The Company recorded a discount on the convertible notes due to a beneficial conversion feature of $18,892.

Table of Contents

Dated March 31, 2020

On March 31, 2020, the Company issued a convertible note with a conversion price of $0.005 to pay operating expenses of $5,834. The convertible note is unsecured, bears interest at 35% per annum, has no maturity date and is due on demand. The Company recorded a discount on the convertible notes due to a beneficial conversion feature of $5,834.

Dated June 30, 2020

On June 30, 2020, the Company issued a convertible note with a conversion price of $0.001 to pay operating expenses of $2,000. The convertible note is unsecured, bears interest at 35% per annum, has no maturity date and is due on demand. The Company recorded a discount on the convertible notes due to a beneficial conversion feature of $2,000.

NOTE 5 - RELATED PARTY TRANSACTIONS

During the ~~three~~six months ended ~~September~~December 3031, 2020, the Company’s sole officer paid $315,~~840~~468 for operating expenses on behalf of the Company. As of ~~September~~December 3031, 2020, the Company was obligated to the officer, for an unsecured, non-interest-bearing demand loan with a balance of $315,~~840~~468.

NOTE 6 – EQUITY

Preferred Stock

The Company is authorized to issue 90,000,000 shares of preferred stock at a par value of $0.0001.

No shares were issued and outstanding as of ~~September~~December 3031, 2020 and June 30,2020, respectively.

Common Stock

The Company is authorized to issue 100,000,000 shares of preferred stock at a par value of $0.0001.

AsDuring atthe ~~September~~six ~~30,~~months ~~2020~~ended ~~and~~December ~~June 30~~31, 2020, 5913,~~423~~820,~~598~~000 shares ~~of common stock~~ were ~~issued and outstanding~~canceled.

As atof ~~September~~December 31, 2020 and June 30, 2020, ~~there~~45,603,598 ~~were~~and no59,423,598 ~~warrants~~shares orof ~~options~~common stock were issued and outstanding.

As of December 31, 2020, there were no warrants or options outstanding.

NOTE 7 – SUBSEQUENT EVENT

Management has evaluated subsequent events through the date these financial statements were available to be issued. Based on our evaluation no material events have occurred that require disclosure.

1112 Table of Contents

Item 2. Management’s Discussion and Analysis of Financial Condition or Plan of Operation

FORWARD-LOOKING STATEMENTS

This quarterly report contains forward-looking statements. These statements relate to future events or our future financial performance. In some cases, you can identify forward-looking statements by terminology such as “may”, “should”, “expects”, “plans”, “anticipates”, “believes”, “estimates”, “predicts”, “potential” or “continue” or the negative of these terms or other comparable terminology. These statements are only predictions and involve known and unknown risks, uncertainties and other factors that may cause our or our industry’s actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements. Except as required by applicable law, including the securities laws of the United States, we do not intend to update any of the forward-looking statements to conform these statements to actual results.

Our consolidated unaudited financial statements are stated in United States Dollars (US$) and are prepared in accordance with United States Generally Accepted Accounting Principles. The following discussion should be read in conjunction with our financial statements and the related notes that appear elsewhere in this quarterly report. The following discussion contains forward-looking statements that reflect our plans, estimates and beliefs. Our actual results could differ materially from those discussed in the forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those discussed below and elsewhere in this quarterly report.

Unless otherwise specified in this quarterly report, all dollar amounts are expressed in United States dollars and all references to “common stock” refer to shares of our common stock.

As used in this quarterly report, the terms “we”, “us”, “our” and “our company” mean Bionovate Technologies Corp., unless otherwise indicated.

Corporate Overview

Our company was incorporated in the State of Nevada on October 24, 2012. Founded in Calgary, Canada, we were formed and organized to capitalize on new opportunities found in the North American market for light-emitting diode (“LED”) lighting. With China as the manufacturing backbone of future LED products, we have set up an office in Guangzhou, China in search of high quality products offered by reputable manufacturers to be introduced to Canada, the United States, and abroad. In November 2016, we expanded our operations to include reselling various energy products and green technology products. We achieved this by acquiring Energy Alliance Labs Inc. (“Energy Alliance”), which is the 80% owner of Human Energy Alliance Laboratories Corp., an Idaho corporation (“HEAL”). HEAL is a “green technology” and retail company with the mission of developing and distributing technologies that relieve its customers of certain burdens, while simultaneously decreasing the energy they use. HEAL’s primary products are mid-sized wind turbines, small solar panels and related controllers and inverters.

On October 28, 2016, we entered into a share exchange agreement with Cohen Mizrahi, a director of our company, whereby on the same date we issued 4,000,000 shares of our common stock in exchange for 100% of the issued and outstanding equity interests of Energy Alliance.

On November 1, 2016, Energy Alliance closed the transactions contemplated under an agreement with certain shareholders of HEAL, in which the shareholders holding 80% of the outstanding equity interests of HEAL sold all of their shares of HEAL to Energy Alliance.

As a result of such transactions we became the owner of 100% of the issued and outstanding equity interests of Energy Alliance and Energy Alliance became the owner of 80% of the issued and outstanding equity interests of HEAL.

Effective October 4, 2016, we filed a Certificate of Dissolution of MJP Holdings Ltd., our wholly-owned subsidiary.

Table of Contents

Effective November 28, 2016, we entered into a Share Exchange Agreement with MJP Lighting Solutions Ltd., a British Virgin Islands (“BVI”) corporation and Tong Tang and Zhao Hui Ma (the “Shareholders”) whereby the parties exchanged 100% of the issued and outstanding shares of BVI, belonging to our company for the tender of 5,500,000 restricted common shares of our company, belonging to the Shareholders, to our treasury for cancellation.

12 Table of Contents

On January 1, 2017, MJP entered into transfer agreement with Cohen Mizrahi, whereby we transferred 100% of the issued and outstanding equity interests of Energy Alliance for consideration of $20,000 for past services provided to our company by Mr. Guo.

On December 1, 2017, a majority of our stockholders and our board of directors approved a change of name of our company to “Bionovate Technologies Corp.” and a reverse stock split of our issued and outstanding shares of common stock on a fifty (50) old for one (1) new basis.

A Certificate of Amendment was filed with the Nevada Secretary of State on December 11, 2017 with an effective date of December 21, 2017.

The name change and reverse split became effective with the OTC Markets at the opening of trading on December 21, 2017 under the symbol “BIIO”.

Effective January 11, 2018, we entered into a Patent Purchase and License Agreement with Lily Innovation Advisors Ltd. wherein we agreed to purchase the rights to U.S. Patent No. 7,963,959 “Automated Cryogenic Skin Treatment” (the “Lily Patent”). We paid $10,000 as consideration for the Lily Patent, and agreed to pay royalties of one percent (1%) of the (a) net sales of all products that are derived from the invention covered under the Lily Patent and sold by our company or any licensees or transferees and (b) licensing fees, royalties or similar payments in respect of the Lily Patent received by any such entity, such royalties to be paid quarterly in January, April, July and October for all sales incurred in the previous calendar quarter.

The assignment of the Lily Patent was registered with the United States Patent and Trademark Office on January 31, 2018.

The foregoing description of the Patent Purchase and License Agreement is included to provide information regarding its terms. It does not purport to be a complete description and is qualified by its entirety by reference to the full text of the Patent Purchase and License Agreement, which is filed as Exhibit 10.1 hereto and is incorporated herein by reference.

Effective February 19, 2018, we entered into a Patent Purchase and License Agreement with Ramot at Tel-Aviv University Ltd. wherein we agreed to purchase the rights to U.S. Patent No. 6,858,007 “Method and system for automatic classification and quantitative evaluation of adnexal masses based on a cross-sectional or projectional images of the adnexs” (the “Ramot Patent”). We paid $10,000 as consideration for the Ramot Patent and agreed to pay royalties of one percent (1%) of the net sales of all products sold by our company that are derived from the invention covered by the Ramot Patent, such royalties to be paid quarterly in January, April, July and October from sales incurred in the previous calendar quarter.

The assignment of the Ramot Patent was registered with the United States Patent and Trademark Office on March 5, 2018.

October 1, 2019, a majority of our shareholders approved a reverse stock split on a basis of 100 old shares for one (1) new share of our issued and outstanding common stock. As a result of the reverse split, our issued and outstanding shares of common stock decreased from 15,579,749 to 155,798 shares of common stock, our authorized capital remained unchanged. The reverse split became effective with the OTC Markets at the opening of trading on January 9, 2020.

Effective January 28, 2020, the Company amended a 20% Convertible Note originally issued on March 31, 2019 (the “Note”). The Note reduces the interest rate from 20% to 0 and changes the conversion price from $0.01 to $0.0001.

Table of Contents

Effective January 28, 2020, the Note was assigned to Evergreen Solutions Ltd., and was immediately converted for the issuance of 54,270,000 shares of common stock of the Company resulting in a change of control.

13On ~~Table~~February 3, 2020, Cohen Mizrahi resigned as a director and as an officer of ~~Contents~~our company. Dr. Mizrahi’s resignation was not the result of a disagreement between Dr. Mizrahi and our company on any matter relating to our company’s operations, policies or practices. On February 3, 2020, David Magana Gonzalez was appointed as a director to replace Dr. Mizrahi and he was also appointed President, Chief Executive Officer, Chief Financial Officer, Secretary and Treasurer of our company. On July 22, 2020, David Magna Gonzalez resigned as a director and as an officer of our company. Mr. Gonzalez’s resignation was not the result of a disagreement between Mr. Gonzalez and our company on any matter relating to our company’s operations, policies or practices. On July 22, 2020, Marc Applbaum was appointed as a director to replace David Magna Gonzolez and he was also appointed President, Chief Executive Officer, Chief Financial Officer, Secretary and Treasurer of our company. On September 28, 2020, Marc Applbaum resigned as a director and as an officer of our company. Mr. Applbaums resignation was not the result of a disagreement between Mr. Applbaum and our company on any matter relating to our company’s operations, policies or practices. On September 28, 2020, Aleksander Vucak was appointed as a director to replace Marc Applbaum and he was also appointed President, Chief Executive Officer, Chief Financial Officer, Secretary and Treasurer of our company.

On February 3, 2020, Cohen Mizrahi resigned as a director and as an officer of our company. Dr. Mizrahi’s resignation was not the result of a disagreement between Dr. Mizrahi and our company on any matter relating to our company’s operations, policies or practices. On February 3, 2020, David Magana Gonzalez was appointed as a director to replace Dr. Mizrahi and he was also appointed President, Chief Executive Officer, Chief Financial Officer, Secretary and Treasurer of our company.On July 22, 2020, David Magna Gonzalez resigned as a director and as an officer of our company. Mr. Gonzalez’s resignation was not the result of a disagreement between Mr. Gonzalez and our company on any matter relating to our company’s operations, policies or practices. On July 22, 2020, Marc Applbaum was appointed as a director to replace David Magna Gonzolez and he was also appointed President, Chief Executive Officer, Chief Financial Officer, Secretary and Treasurer of our company. On September 28, 2020, Marc Applbaum resigned as a director and as an officer of our company. Mr. Applbaums resignation was not the result of a disagreement between Mr. Applbaum and our company on any matter relating to our company’s operations, policies or practices. On September 28, 2020, Aleksander Vucak was appointed as a director to replace Marc Applbaum and he was also appointed President, Chief Executive Officer, Chief Financial Officer, Secretary and Treasurer of our company.

On October 7, 2020, Bionovate Technologies Corp. (the “Company”) entered into a Share Exchange Agreement (the “Share Exchange Agreement”) facilitated between Evergreen Solutions, Ltd, a private Company (“Evergreen”), and Human Data AG, a private Switzerland Company (“Human Data”).

Pursuant to the Share Exchange Agreement, in exchange for the acquisition of all of the outstanding Company shares which Evergreen owns, to wit, 54,270,000 shares (the “Exchange Shares”), the Company will receive 12,500 shares of Digital Diagnostics AG (“Digital”) owned by Human Data, which equates to 25% of the currently issued shares of Digital.

On December 4, 2020, 13,820,000 shares were canceled by the CEO.

Our corporate address is Gewerbestrasse 10, Cham, Switzerland 6330. We do not have a corporate website.

We do not have any subsidiaries.

We have not been subject to any bankruptcy, receivership, or similar proceeding.

Current Business

WeBionovate ~~are~~Technologies ~~a medical device company that intends to develop the first automated treatment for age spots (solar lentigines)~~Corp. ~~The~~focuses ~~technology~~on ~~(patent~~investments ~~issued) uses a “scan~~ and ~~treat” protocol that removes age spots accurately and completely without disturbing~~ the ~~surrounding~~marketing ~~skin area. Current methods~~ of ~~treatment~~patents ~~(lasers~~ and ~~manual~~licenses ~~liquid~~which ~~nitrogen~~bring ~~spray~~healthcare ~~devices)~~and ~~are~~lifestyle ~~either~~diagnostics ~~painful, costly, or require a physician~~ to ~~perform~~your ~~the procedure~~smartphone. ~~The~~With ~~Bionovate~~strong ~~system~~emphasis ~~would~~on bedigital ~~safe~~transformation, ~~and~~the ~~would~~company ~~produce~~intends ~~excellent~~to ~~results~~build ~~and~~an ~~can~~FDA-approved beecosystem ~~used for other types~~ of ~~skin~~medical ~~lesions.~~devices, ~~Its~~biosensors ~~operation~~and ~~would~~mobile ~~require~~applications ~~minimal~~to ~~user~~turn ~~interaction~~tests ~~and~~that ~~users~~were ~~can~~previously beonly ~~trained~~done in ~~minutes.~~physical Welabs ~~are also looking~~ into ~~developing~~tests ~~novel~~that ~~cancer~~can ~~detection~~be ~~methods~~carried ~~based~~through onby ~~its~~anyone ~~electronic~~with ~~imaging~~a ~~patent~~mobile device.

1415 Table of Contents

Results of Operations

Our operations for the three and six ended ~~September~~December 3031, 2020 and 2019 are outlined below:

Three months ended ~~September~~December 3031, 2020 compared to three months ended ~~September~~December 3031, 2019.

	Three Months Ended
	September 30,				Change
	December 31,				Change
	2020		2019		Amount			%
Revenues	$	-	$	-	$	-			-
Operating Expenses		320,~~622~~688		1310,~~412~~950		(9,~~790~~738	)	~~(73~~	89	)%
Total other expense		1911,~~252~~746		1534,~~964~~619		3(22,~~288~~873	)		21(66	)%
Net Loss	$	2232,~~874~~434	$	2945,~~376~~569	$	(613,~~502~~135	)	~~(22~~	(29	)%

For the three months ended ~~September~~December 3031, 2020 and 2019, we had no revenue. Expenses for the three months ended ~~September~~December 3031, 2020 totaled $2232,~~874~~434 resulting in a net loss of $2232,~~874~~434 as compared to a net loss of $2945,~~376~~569 for the three months ended ~~September~~December 3031, 2019. The decrease in net loss for the three months ended ~~September~~December 3031, 2020 is a result of a decrease in ~~professional~~interest ~~fees~~expense offset by an increase in ~~interest~~professional ~~expense~~fee.

Six months ended December 31, 2020 compared to six months ended December 31, 2019.

	Six Months Ended
	December 31,				Change
	2020		2019		Amount			%
Revenues	$	-	$	-	$	-			-
Operating Expenses		24,310		24,362		(52	)	(0%)
Total other expense		30,998		50,583		(19,585	)		(39	)%
Net Loss	$	55,308	$	74,945	$	(19,637	)		(26	)%

For the six months ended December 31, 2020 and 2019, we had no revenue. Expenses for the six months ended December 31, 2020 totaled $55,308 resulting in a net loss of $55,308 as compared to a net loss of $74,945 for the six months ended December 31, 2019. The decrease in net loss for the six months ended December 31, 2020 is a result of a decrease in interest expense.

Liquidity and Capital Resources

The following table provides selected financial data about our company as of ~~September~~December 3031, 2020 and June 30, 2020, respectively.

Working Capital

	September 30,			June 30,			Change
	December 31,			June 30,			Change
	2020			2020			Amount			%
Current Assets	$	-		$	-		$	-			-
Current Liabilities	$	~~419~~451,~~539~~973		$	396,665			2255,~~874~~308			614	%
Working Capital (Deficit)	$	(~~419~~451,~~539~~973	)	$	(396,665	)	$	(2255,~~874~~308	)		614	%

Table of Contents

Cash Flows

	Three Months Ended
	Six Months Ended
	September 30,
	December 31,
	2020		2019
Net Cash Provided by Operating Activities	$	-	$	-
Net Cash Provided by Investing Activities	$	-	$	-
Net Cash Provided by Financing Activities	$	-	$	-
Net Change in Cash During the Period	$	-	$	-

On ~~September~~December 3031, 2020, our Company’s cash balance was $0 and total assets were $0. On June 30, 2020, our Company’s cash balance was $0 and total assets were $0.

On ~~September~~December 3031, 2020, our Company had total liabilities of $~~419~~451,~~539~~973, compared with total liabilities of $396,665 as at June 30, 2020.

On ~~September~~December 3031, 2020, our Company had working capital deficiency of $~~419~~451,~~539~~973 compared with working capital deficiency of $396,665 as at June 30, 2020. The increase in working capital was primarily attributed to an increase in accounts payable and accrued liabilities and due to related party.

Cash Flow from Operating Activities

During the ~~three~~six months ended ~~September~~December 3031, 2020, our Company provided $0 by operating activities, compared to $0 provided by operating activities during the ~~three~~six months ended ~~September~~December 3031, 2019.

15 Table of Contents

Cash Flow from Investing Activities

During the ~~three~~six months ended ~~September~~December 3031, 2020 and 2019, our Company did not have any investing activities.

Cash Flow from Financing Activities

During the ~~three~~six months ended ~~September~~December 3031, 2020 and 2019, our Company did not have any investing activities.

Off-Balance Sheet Arrangements

We have no off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, and capital expenditures or capital resources that are material to stockholders.

Critical Accounting Policies

Revenue Recognition

Revenues are recognized when control of the promised goods or services are transferred to a customer, in an amount that reflects the consideration that the Company expects to receive in exchange for those goods or services. The Company applies the following five steps in order to determine the appropriate amount of revenue to be recognized as it fulfills its obligations under each of its agreements:

	·	identify the contract with a customer;
	·	identify the performance obligations in the contract;
	·	determine the transaction price;
	·	allocate the transaction price to performance obligations in the contract; and
	·	recognize revenue as the performance obligation is satisfied.

Table of Contents

Recent Accounting Pronouncements

We have implemented all new accounting pronouncements that are in effect and that may impact our financial statements and does not believe that there are any other new accounting pronouncements that have been issued that might have a material impact on our financial position or results of operations. Our company regularly reviews and analyses the recent accounting pronouncements.

16 Table of Contents

Item 3. Quantitative and Qualitative Disclosures About Market Risk

As a “smaller reporting company”, we are not required to provide the information required by this Item.

Item 4. Controls and Procedures

Evaluation of Disclosure Controls and Procedures

Our management is responsible for establishing and maintaining a system of disclosure controls and procedures (as defined in Rule 13a-15(e) and 15d-15(e) under the Exchange Act) that is designed to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the Commission’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by an issuer in the reports that it files or submits under the Exchange Act is accumulated and communicated to the issuer’s management, including its principal executive officer or officers and principal financial officer or officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.

An evaluation was conducted under the supervision and with the participation of our management of the effectiveness of the design and operation of our disclosure controls and procedures as of March 31, 2020. Based on that evaluation, our management concluded that our disclosure controls and procedures were not effective as of such date to ensure that information required to be disclosed in the reports that we file or submit under the Exchange Act, is recorded, processed, summarized and reported within the time periods specified in SEC rules and forms. Such officer also confirmed that there was no change in our internal control over financial reporting during the period ended March 31, 2020, that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

Changes in Internal Control Over Financial Reporting

There have been no changes in our internal control over financial reporting that occurred during the quarter ended ~~September~~December 3031, 2020, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

1718 Table of Contents

PART II - OTHER INFORMATION

Item 1. Legal Proceedings

We know of no material, existing or pending legal proceedings against our Company, nor are we involved as a plaintiff in any material proceeding or pending litigation. There are no proceedings in which any of our directors, officers or affiliates, or any registered beneficial shareholder, is an adverse party or has a material interest adverse to our interest.

Item 1A. Risk Factors

As a “smaller reporting company”, we are not required to provide the information required by this Item.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

None.

Item 3. Defaults Upon Senior Securities

None.

Item 4. Mine Safety Disclosures

Not Applicable.

Item 5. Other Information

None

1819 Table of Contents

Item 6. Exhibits

Exhibit Number		Description
(31)		Rule 13a-14 (d)/15d-14d) Certifications
31.1*		Section 302 Certification under the Sarbanes-Oxley Act of 2002
(32)		Section 1350 Certifications
32.1*		Section 906 Certification under the Sarbanes-Oxley Act of 2002
101*		Interactive Data File
101.INS**		XBRL Instance Document
101.SCH**		XBRL Taxonomy Extension Schema Document
101.CAL**		XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF**		XBRL Taxonomy Extension Definition Linkbase Document
101.LAB**		XBRL Taxonomy Extension Label Linkbase Document
101.PRE**		XBRL Taxonomy Extension Presentation Linkbase Document

* Filed herewith.

** XBRL Information is furnished and not filed or a part of a registration statement or prospectus for purposes of Sections 11 or 12 of the Securities Act of 1933, as amended, is deemed not filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and otherwise is not subject to liability under these sections.

1920 Table of Contents

SIGNATURES

In accordance with Section 13 or 15(d) of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

		BIONOVATE TECHNOLOGIES CORP.
		(Registrant)
Dated: November 23, 2020		/s/ Aleksander Vucak
Dated: January 28, 2021		/s/ Aleksander Vucak
		Aleksander Vucak
		President, Chief Executive Officer, Chief Financial Officer, Secretary, Treasurer and Director
		(Principal Executive Officer, Principal Financial Officer and Principal Accounting Officer)

2021

Filing Compare · Bionovate Technologies Corp.